🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →
S&P 500: 769.60 -1.1% NASDAQ 100: 728.95 -2.0% Dow Jones: 534.08 -0.5%

Boxer Capital Management - Q1 2026 13F Filings

BO

Boxer Capital Management, LLC

CIK: 0002018299
Address: California San Diego 12860 El Camino Real Suite 300
$761.65 M
Portfolio Value
54
Assets Held
Reporting Period: Q1 2026
Filing Status:
Active
Last Updated: 08/14/2026

Portfolio Summary (Q1 2026)

View Full Portfolio Analysis

Top Buys

Q1 2026
1. PCVX Vaxcyte
+$18.89 M
2. CRVS Corvus Pharmaceuticals
+$16.09 M
3. DFTX Definium Therapeutics
+$11.31 M
4. VIR Vir Biotechnology
+$11.12 M
5. IRD Opus Genetics
+$10.24 M

Top Sells

Q1 2026
1. CDTX Cidara Therapeutics
−$11.71 M
2. MNMD Mind Medicine (Mindmed)
−$8.01 M
3. CBIO Crescent Biopharma
−$5.38 M
4. CYBN Cybin
−$360,000
5. PEPG Pepgen
−$178,770.06

Asset Allocation

Stocks/ETFs
+66.74%
$761.65 M 100.00%
Options
$0 0.00%
Debt
$0 0.00%
Other
-98.81%
$1,067 0.00%

Sector Allocation (Stocks)

Boxer Capital Management Q1 2026 Filing Summary

Boxer Capital Management, LLC filed its 13F report for Q1 2026 on May 15, 2026. The portfolio totaled 761.65 M reflecting a +66.71% change from the prior quarter, spanning 54 assets. The top 10 holdings comprised 63.3% of the portfolio, with Financials as the largest sector allocation. Quarterly activity included 13 new positions and 3 complete exits.

Report Type

Status

Data Summary

Items:

Total Value:

Actions

Issuer Name Class Value Shares Option Type

FAQs for Boxer Capital Management’s Q1 2026 Filing

Boxer Capital Management submitted their Form 13F-HR for the Q1 2026 period on 05/15/2026. This was the only submission for the quarter.

In the Q1 2026 filing, Boxer Capital Management reported a managed portfolio value of 761.65 M, consisting of 54 individual positions.

This page displays the raw filing documents. To see which stocks Boxer Capital Management bought or sold during Q1 2026, please visit Boxer Capital Management's Portfolio Analysis page.